Results 221 to 230 of about 156,514 (326)

Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials [PDF]

, 2019
Atul R. Mahableshwarkar, John Affinito, Elin Heldbo Reines, Judith Xu, George G. Nomikos, Paula L. Jacobsen   +5 more
openalex   +1 more source

Main factors associated with variability in the assessment of the objective response rate. A re‐analysis of the PHEREXA phase 3 clinical trial

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Local investigators (LIs) overestimate the objective response rate (ORR) in comparison to Blinded Independent Central Reviewers (BICR) in oncology. In this study, we re‐analysed data obtained in the PHEREXA trial (NCT01026142) with the following aims: i) to confirm at the single‐patient level the discrepancy observed by analysing ...
Gennaro Daniele, Tommaso Giovagnoli, Pierluigi Navarra, Cinzia Dello Russo   +3 more
wiley   +1 more source

Pharmacokinetics of Staccato^® alprazolam in healthy adult participants in two phase 1 studies: An open‐label smoker study and a randomized, placebo‐controlled ethnobridging study [PDF]

Yoshinobu Hayakawa, Chiara Rospo, Ana Paula Bartmann, Aliceson King, Robert Roebling, Hugues Chanteux   +5 more
openalex   +1 more source

Regulation Through Revelation: The Effect of Pollution Monitoring on Labour Demand

Business Strategy and the Environment, EarlyView.
ABSTRACT This paper investigates how manufacturing firms respond to a real‐time pollution monitoring programme, with a focus on the implication for employment. Contrary to the conventional expectation that environmental regulations negatively impact business, the findings reveal that enhanced pollution monitoring has a significant and robust positive ...
Tong Zhu, Andreas Löschel
wiley   +1 more source

Open-Label Placebos as Adjunct for the Preventive Treatment of Migraine: A Randomized Clinical Trial.

JAMA Netw Open
Kleine-Borgmann J, Schmidt K, Ludwig L, Schulz M, Holle-Lee D, Gaul C, Bingel U.   +6 more
europepmc   +1 more source

Does Managerial Ability Improve Environmental Performance and Overall ESG Ratings? The Impact of the European Sustainability Reporting Mandate

Business Strategy and the Environment, EarlyView.
ABSTRACT This study examines the role of managerial ability in driving environmental performance and overall environmental, social, and governance (ESG) ratings in the context of the European Union sustainability reporting regulations. Using a sample of 7242 firm‐year observations over the period 2015–2023, our results indicate a structural change in ...
Mihaela Ionașcu, Ion Ionașcu, Elena Turuianu   +2 more
wiley   +1 more source

Contemporary and Emerging Therapies in the Management of Refractory Angina: A Clinical Review

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Refractory angina (RA) represents a growing challenge in clinical cardiology, particularly in patients with obstructive coronary artery disease (CAD) who remain symptomatic despite optimal medical therapy and who are not candidates for revascularization.
Alex Angers‐Goulet, Siddhartha Mengi, David Garcia Labbé, Can Manh Nguyen, Jean‐Michel Paradis   +4 more
wiley   +1 more source

Effects of High‐ and Low‐Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Votoplam is a novel, orally bioavailable, small molecule HTT gene splicing modifier that is being developed for the treatment of Huntington's disease. This was a single dose, open‐label, two‐period, crossover food effect study that evaluated the effect of high‐ and low‐fat meals on 20 mg votoplam in healthy participants. There was a washout of
Lucy Lee, Amy‐Lee Richards, Nageswara Reddy, Brian Beers, Lee Golden, Ronald Kong   +5 more
wiley   +1 more source

Boosting open-label placebo effects in acute induced pain in healthy adults (BOLPAP-study): study protocol of a randomized controlled trial [PDF]

Matthijs de Leeuw, Mirjam Laager, Jens Gaab, Wilhelm Ruppen, Tobias Schneider   +4 more
openalex   +1 more source

A Phase 1, Randomized, Placebo‐Controlled, Multiple‐Dose, Double‐Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian Individuals

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This Phase 1, randomized, placebo‐controlled, double‐blind study assessed the pharmacokinetic profile of rimegepant (25, 75, or 150 mg once daily for 14 days) in healthy Japanese and Caucasian adults. Exposures were modestly increased in Japanese participants compared with Caucasian participants following a single dose of rimegepant (Day 1 ...
Rajinder Bhardwaj, Chay Ngee Lim, Yinhua Li, Kyle T. Matschke, Richard Bertz, Robert Croop, Jing Liu   +6 more
wiley   +1 more source